SCHEMBL24252506

SCHEMBL24252506

Cc1nnc(N)c2ccc(-c3cc(B(O)O)ccc3F)cc12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.37
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36
PLG P00747 1/20 0.34
F12 P00748 1/20 0.34
F11 P03951 1/20 0.34
KLKB1 P03952 1/20 0.34
PRSS1 P07477 1/20 0.34
PRSS2 P07478 1/20 0.34
PRSS3 P35030 1/20 0.34
PIM1 P11309 1/20 0.33
SRC P12931 1/20 0.33
GSK3A P49840 1/20 0.33
TGFBR1 P36897 1/20 0.32
EPHB4 P54760 1/20 0.30
PRKACA P17612 1/20 0.30
PRKACG P22612 1/20 0.30
PRKACB P22694 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL30467607 0.94 PDGFRB (0.36) MAP4K4PDGFRBKDRPLGF12
SCHEMBL26771045 0.91 MAP4K4 (0.36) MAP4K4PDGFRBKDRPIM1SRC
SCHEMBL24252263 0.87 MAP4K4 (0.37) MAP4K4PLGF12F11KLKB1
SCHEMBL24252277 0.84 TRPA1 (0.34) PLGF12F11KLKB1PRSS1
SCHEMBL24252269 0.83 DHFR (0.40) MAP4K4PLGF12F11KLKB1
SCHEMBL24252663 0.83 PLG (0.33) PLGF12F11KLKB1PRSS1
SCHEMBL24252685 0.82 PDGFRB (0.32) PDGFRBKDR
Formic Acid SCHEMBL25268266 0.82 MAP4K4 (0.34) MAP4K4PLGF12F11KLKB1
SCHEMBL24252366 0.82 ABL1 (0.33) PLGF12F11KLKB1PRSS1
SCHEMBL30451875 0.82 ABL1 (0.33) PLGF12F11KLKB1PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 MAP4K4 2769/4885PDGFRB 1234/4885KDR 3397/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 MAP4K4 2769/4885PDGFRB 1234/4885KDR 3397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.